Table 1 Participants’ characteristics compared between analyzed participants and participants lost to follow-up
Participants included (N = 207) n (%) | Participants lost to follow-up (N = 27) n (%) | p-value | |
|---|---|---|---|
Gender | |||
Male | 60 (29.4) | 2 (7.7) | 0.0181 |
Female | 144 (70.6) | 24 (92.3) | |
Age, years | |||
Mean (sd) | 51.9 (13.9) | 58.6 (14.3) | 0.0303 |
< 40 | 44 (21.4) | 3 (11.1) | 0.2061 |
40–65 | 127 (61.7) | 16 (59.3) | |
> 65 | 35 (17.0) | 8 (29.6) | |
School education | |||
Lower | 16 (8.1) | 4 (15.4) | 0.2032 |
Middle | 59 (29.8) | 11 (42.3) | |
Upper | 121 (61.1) | 11 (42.3) | |
Other | 2 (1.0) | 0 (0.0) | |
Previous COVID infection | |||
Yes | 3 (1.5) | 0 (0.0) | 11 |
First administered vaccine | |||
BNT162b2 (Pfizer/BioNTech) | 131 (67.5) | 17 (89.5) | 0.1382 |
AZD 1222 (AstraZeneca) | 42 (21.6) | 2 (10.5) | |
mRNA-1,273 (Moderna) | 21 (10.8) | 0 (0.0) | |
Underlying diseasea | |||
Organ transplant | 14 (6.8) | 2 (7.4) | 11 |
Inflammatory bowel disease | 38 (18.4) | 2 (7.4) | 0.1851 |
Rheumatic disease | 99 (47.8) | 15 (55.6) | 0.5411 |
Multiple sclerosis | 20 (9.7) | 1 (3.7) | 0.4821 |
Psoriasis | 30 (14.5) | 5 (18.5) | 0.5691 |
Other | 3 (11.1) | 29 (14.0) | 11 |
Immunosuppressantsa | |||
Conv. immunosuppressants | 92 (44.4) | 14 (51.9) | 0.5391 |
Corticoids | 72 (34.8) | 10 (37.0) | 0.8321 |
TNF inhibitor | 39 (18.8) | 6 (22.2) | 0.6131 |
Other biologicals | 39 (18.8) | 5 (18.5) | 11 |
Other | 51 (24.6) | 7 (25.9) | 11 |
Number of taken immunosuppressants | |||
1 | 132 (63.8) | 15 (55.6) | 0.7352 |
2 | 54 (26.1) | 9 (33.3) | |
3 or more | 21 (10.1) | 3 (11.1) | |